<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-78732</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Cabergoline in hyperprolactinemia and valvular heart disease</dc:title>
<dc:description xml:lang="en">Introduction: High-dose cabergoline therapy has been related to cardiac valve regurgitation in patients with Parkinson&#146;s disease. Aims: To perform a systematic analysis of reports on low-dose cabergoline treatment in hyperprolactinemia and its effect on the cardiac valves. Results: None of the seven reports analyzed, including 463 patients in total, found clinically significant valve regurgitation. Only one report found moderate tricuspid valve regurgitation, and other two reports found mild tricuspid valve regurgitation. An increase in the mitral tenting area was documented in only one of two reports. Valve thickening and calcifications were found in only one study. Conclusions: Cabergoline seems to be safe at the doses employed in hyperprolactinemic patients. There is a higher prevalence of tricuspid regurgitation, detected by systematic echocardiography, but this abnormality is asymptomatic. Although prospective longitudinal studies are needed, vigilance of these patients is recommended, especially those treated with high-dose cabergoline (AU)</dc:description>
<dc:creator>Alameda Hernando, Carmen</dc:creator>
<dc:creator>Lahera Vargas, Marcos</dc:creator>
<dc:creator>Escobar Cervantes, Carlos</dc:creator>
<dc:creator>Varela da Costa, César</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: La cabergolina a dosis elevadas se ha relacionado con insuficiencia valvular y retracción y engrosamiento valvular en pacientes con enfermedad de Parkinson. Objetivos: Realizar un análisis sistemático de las publicaciones sobre pacientes con hiperprolactinemia tratados con cabergolina y su efecto en las válvulas cardíacas. Resultados: Ninguna de las 7 series revisadas, con 463 pacientes en total, detectó insuficiencia valvular clínicamente significativa. Se encontró insuficiencia tricuspídea (IT) moderada sólo en un estudio, e IT ligera en otras 2 publicaciones. El aumento del área de tenting mitral sólo se ha demostrado en uno de los dos estudios realizados. Hubo calcificaciones y engrosamiento valvular solamente en una de las series. Conclusiones: La cabergolina parece ser segura a las dosis empleadas en la hiperprolactinemia. Hay aumento de prevalencia de IT como hallazgo ecográfico, pero es asintomática. Aunque se precisan estudios longitudinales prospectivos, se recomienda la vigilancia de los pacientes tratados, especialmente con dosis elevadas (AU)</dc:description>
<dc:source>Endocrinol Nutr;56(8): 412-417, oct. 2009. tab</dc:source>
<dc:identifier>ibc-78732</dc:identifier>
<dc:title xml:lang="es">Cabergolina en la hiperprolactinemia y enfermedad vascular cardíaca</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d4956^s22073</dc:subject>
<dc:subject>^d4956^s22020</dc:subject>
<dc:subject>^d20186^s22057</dc:subject>
<dc:subject>^d6501^s22036</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d32276^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:type>article</dc:type>
<dc:date>200910</dc:date>
</metadata>
</record>
</ibecs-document>
